ClaudineIsaacsMDFRCPC

Breast Cancer, Cancer Genetics/Cancer Risk Assessment

Professor, Medicine, MedStar Georgetown University Hospital, Georgetown University Medical Center

Dr. Isaacs is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Georgetown University HospitalFellowship, Medical Oncology, 1993
MedStar Health/Georgetown-Washington Hospital CenterFellowship, Hematology and Medical Oncology, 1993
McGill University Faculty of MedicineClass of 1987

America's Top Doctors Castle Connolly, 2006-2022
Top Doctors: Washington DC Washingtonian Magazine, 2012, 2015-2022
America's Top Doctors for Cancer Castle Connolly, 2005-2022
Northern Virginia Top Doctors Northern Virginia Magazine, 2007-2008, 2019
CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2013
Top Doctors:Washington-Baltimore Castle Connolly, 2012
Women's Health Castle Connolly, 2008
Whos Who in Medicine and Healthcare Marquis Whos Who
Join now to see all

PubMed

166 citations
Prognostic factors in breast cancer: current and new predictors of metastasis.
Daniel F. Hayes, Claudine Isaacs, Vered Stearns
Journal of Mammary Gland Biology and Neoplasia. 2001-10-01
825 citations
The national lung screening trial: Overview and study design
Constantine A. Gatsonis, Denise R. Aberle, Christine D. Berg, William C. Black, Timothy R. Church
Radiology. 2011-01-01
32 citations
Population-based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 years.
Arnold L. Potosky, Suzanne C. O'Neill, Claudine Isaacs, Huei-Ting Tsai, Calvin Chao
Cancer. 2015-11-15

Journal Articles

Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy with Disease Recurrence in Patients with Triple-Negative Breast Cancer
Rita Nanda, Carla Falkson, Filipa C Lynce, Claudine Isaacs, Marcelo Blaya, Elisavet Paplomata, Radhika Walling, Reshma Mahtani, Tarah J Ballinger, Kathy D Miller, Brya..., JAMA Oncology

Other

Genetic testing for hereditary breast and ovarian cancer syndrome
Isaacs C, Peshkin BN, Fletcher SW
http://www.uptodate.com/contents/genetic-testing-for-hereditary-breast-and-ovarian-cancer-syndrome
UpToDate, Wolters Kluwer Health - 2012-08-13
Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations
Isaacs C, Peshkin BN, Fletcher SW
http://www.uptodate.com/contents/management-of-hereditary-breast-and-ovarian-cancer-syndrome-and-pat
UpToDate, Wolters Kluwer Health - 2013-04-10
Characteristics of hereditary breast and ovarian cancer syndromes
Isaacs C, Peshkin BN
http://www.uptodate.com/contents/characteristics-of-hereditary-breast-and-ovarian-cancer-syndromes
UpToDate, Wolters Kluwer Health - 2012-12-11
Genetic risk assessment for individuals at risk for hereditary breast and ovarian cancer syndromes
Isaacs C, Peshkin BN
http://www.uptodate.com/contents/genetic-risk-assessment-for-individuals-at-risk-for-hereditary-brea
UpToDate, Wolters Kluwer Health - 2013-02-12
Join now to see all

Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy with Disease Recurrence in Patients with Triple-Negative Breast CancerJuly 2020

Anti-PD-1/Anti-LAG-3 Combination Highly Effective in HER2-Negative Breast CancerDecember 20th, 2022
High Rates of pCR with Novel Neoadjuvant Combination for Breast CancerDecember 11th, 2022
Breast Cancer Myths vs. Facts | VerifyOctober 28th, 2022
Join now to see all